title: Fracture risk in early postmenopausal women assessed using FRAX.
abstract: OBJECTIVE
  To evaluate FRAX 10-year fracture probabilities depending on the recommended management strategy in early postmenopausal women who were untreated at baseline.
  
  
  METHODS
  We conducted a descriptive study in 494 untreated women aged 45-60 years seen for the first time at a menopause clinic. Risk factors, physical findings, and bone mineral density (BMD) values determined by dual-energy X-ray absorptiometry were collected. At the end of the clinic visit, 128 (26%) women were prescribed medications. Then, the 10-year fracture probability was estimated using the FRAX tool.
  
  
  RESULTS
  The mean FRAX probability was 3.9%+/-2% for major osteoporotic fractures and 0.8%+/-0.9% for hip fractures. Women who were prescribed medications had significantly (P<0.001) higher probabilities than the other women. The proportion of women prescribed medications increased significantly (P<0.0001) with the FRAX probability, from 7.8% in the lowest quintile (Q1) to 50.5% in Q5. Hormone replacement therapy or raloxifene contributed 92% of the prescriptions in patients with FRAX probabilities in the first four quintiles and bisphosphonates 70% of prescriptions in patients with probabilities in Q5.
  
  
  CONCLUSIONS
  Early postmenopausal women had low to moderate fracture risks (FRAX, 3-4%). The indications and type of drugs prescribed correlated with FRAX probabilities. Treatment thresholds should be defined to optimize the management of osteoporosis. In early postmenopausal women, treatment thresholds may vary with the type of treatment.
authors.affiliation: Centre de ménopause, hôpital Paule-de-Viguier, 330, avenue de Grande-Bretagne, TSA 70034, 31059 Toulouse cedex 9, France. tremollieres.f@chu-toulouse.fr
authors.forename: Florence
authors.initials: F
authors.lastname: Trémollieres
authors.forename: Tiffany
authors.initials: T
authors.lastname: Cochet
authors.forename: Clémentine
authors.initials: C
authors.lastname: Cohade
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Pouillès
authors.forename: Claude
authors.initials: C
authors.lastname: Ribot
mesh_terms: D015502:Absorptiometry, Photon; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D050723:Fractures, Bone / Q000453:epidemiology*; D005602:France; D006620:Hip Fractures / Q000453:epidemiology; D006801:Humans; D008875:Middle Aged; D015233:Models, Statistical; D015663:Osteoporosis, Postmenopausal / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D020849:Raloxifene Hydrochloride